Stonegate Capital Partners Updates Coverage on Burcon Nutrascience Corporation (BU) FY26 Q2

Executive Summary

• Burcon Nutrascience reported $0.36 M revenue in 2Q26 – a 783% YoY increase driven by initial sales of Puratein® C canola protein and contract manufacturing.
• The company secured up to $4.0 M of unsecured convertible debentures plus a $0.7 M short‑term loan, with at least $2.0 M of insider participation.
• Post‑quarter commercial traction includes the first commercial production of Puratein® C and FavaPro fava protein and more than $500 k in additional sales orders received after quarter‑end.

Key Details

• Revenue: $0.36 M for 2Q26, representing a 783% increase versus the prior year period.
• Commercial Production Milestones:
• First commercial production and sales of Puratein® C canola protein.
• First commercial production of FavaPro fava protein.
• Ongoing scale‑up of Peazazz® C pea protein at the Galesburg facility.
• Post‑Quarter Sales Orders: > $500,000 in new commercial sales orders received after quarter‑end, including the first sale of FavaPro.
• Financing Arrangements:
• Up to $4.0 M unsecured convertible debentures (terms not disclosed).
• $0.7 M short‑term loan; at least $2.0 M of the financing is being provided by insiders.
• Strategic Impact: The combined operational flexibility and strengthened balance sheet position Burcon to meet evolving customer demand quickly with consistent product quality.

Notable Quotes

(No direct quotes were included in the release.)